The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy

Documenti analoghi

• The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
  di: Meiqin Yuan, et al.
  Pubblicazione: (2022-03-01)
• Clinically Based Cetuximab Re-Challenge in Patients with <i>RAS</i> Wild-Type Metastatic Colorectal Cancer and Retrospective Analysis of Liquid Biopsies—Preliminary Data
  di: Zhasmina Mihaylova, et al.
  Pubblicazione: (2025-06-01)
• CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
  di: Stefania Napolitano, et al.
  Pubblicazione: (2022-06-01)
• Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
  di: Alessandro Parisi, et al.
  Pubblicazione: (2021-10-01)
• CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
  di: Yuankai Shi, et al.
  Pubblicazione: (2019-05-01)